Cooley Helps HyperBranch Defeat Patent Infringement Claims

Reston – June 15, 2018 – Cooley successfully defended HyperBranch Medical Technology against a patent infringement lawsuit filed by a competitor, Integra LifeSciences. After a two-week trial in Delaware federal district court, a jury found in favor of HyperBranch on all claims and defenses. Cooley partners Jon Graves and Adam Pivovar led the team representing HyperBranch.

“Jon Graves and Adam Pivovar led a team of talented lawyers and expert witnesses that, over the course of almost three years, successfully defeated a preliminary injunction attempt and the infringement case itself,” said Jeff Clark, CEO of HyperBranch.

The lawsuit, filed in 2015 just two months after HyperBranch launched its Adherus AutoSpray Dural Sealant product in the United States, originally contended that HyperBranch willfully infringed 109 claims in six patents through its manufacture, use and sale of its Adherus products. Integra also filed with its complaint a motion for a preliminary injunction asking the Court to enjoin HyperBranch from making and selling the accused Adherus products during the pendency of the case. 

HyperBranch defeated Integra’s preliminary injunction motion in 2016 and continued to score victories throughout the subsequent litigation. After hearing six days of testimony from witnesses and viewing numerous exhibits admitted into evidence, the jury unanimously determined that the company did not infringe any of the remaining asserted patent claims, and that all of those claims are invalid. 

“We absolutely made the correct decision in selecting Cooley,” Clark added. “The team was fully committed to the case as if they were HyperBranch employees and worked tirelessly to its successful conclusion. For the relationship that developed and the outstanding result, we are exceedingly grateful."

HyperBranch is a medical technology company focused on delivering superior patient and physician experiences through products designed to minimize post-surgical complications. 

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.